Identifying and managing inhibitor patients requiring orthopaedic surgery - the multidisciplinary team approach.
Until recently, surgery in haemophilia patients with inhibitors was strongly contraindicated and was therefore often not even contemplated. Inhibitor patients entering the surgical arena face unique challenges; the most frequently encountered problem during surgical intervention is bleeding, and thrombosis is occasionally observed. The activated prothrombin complex concentrate, FEIBA(TM), and recombinant activated factor VII (rFVIIa) are available as haemostatic cover during surgery. The use of rFVIIa enables inhibitor patients to undergo orthopaedic surgery with an expectation of success, and results are generally good. An organized team approach is critical to this success. However, further information is required to enable different procedures to be optimized in terms of both outcome and safety.
Ludlam
C
C
Department of Haematology, Royal Infirmary of Edinburgh, UK. christopher.ludlam@ed.ac.uk
D019774:Blood Coagulation Factor Inhibitors / Q000097:blood*; D005167:Factor VII / Q000627:therapeutic use; D015942:Factor VIIa; D006467:Hemophilia A / Q000628:therapy*; D006488:Hemostasis, Surgical / Q000379:methods*; D006801:Humans; D008297:Male; D019637:Orthopedic Procedures; D011994:Recombinant Proteins / Q000627:therapeutic use
D019774:Blood Coagulation Factor Inhibitors; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa